EXEL Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 24.68% compared to Exelixis's net margin of 16.72%. Exelixis's return on equity of 23.63% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Exelixis has a consensus price target of $37.06, signalling upside risk potential of 1.12%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.64 which suggests that it could grow by 37.73%. Given that Biomarin Pharmaceutical has higher upside potential than Exelixis, analysts believe Biomarin Pharmaceutical is more attractive than Exelixis.

Exelixis has a beta of 0.571, which suggesting that the stock is 42.856% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.330, suggesting its less volatile than the S&P 500 by 67.009%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Exelixis's net income of $139.9M is higher than Biomarin Pharmaceutical's net income of $124.9M. Notably, Exelixis's price-to-earnings ratio is 20.71x while Biomarin Pharmaceutical's PE ratio is 31.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.00x versus 4.83x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 24.68% compared to Exelixis's net margin of 39.44%. Exelixis's return on equity of 23.63% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Exelixis has a consensus price target of $37.06, signalling upside risk potential of 1.12%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.33 which suggests that it could grow by 58.58%. Given that Catalyst Pharmaceuticals has higher upside potential than Exelixis, analysts believe Catalyst Pharmaceuticals is more attractive than Exelixis.

Exelixis has a beta of 0.571, which suggesting that the stock is 42.856% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.836, suggesting its less volatile than the S&P 500 by 16.449%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are larger than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Exelixis's net income of $139.9M is higher than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Exelixis's price-to-earnings ratio is 20.71x while Catalyst Pharmaceuticals's PE ratio is 16.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.00x versus 5.34x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Halozyme Therapeutics has a net margin of 24.68% compared to Exelixis's net margin of 45.98%. Exelixis's return on equity of 23.63% beat Halozyme Therapeutics's return on equity of 162.37%.

Exelixis has a consensus price target of $37.06, signalling upside risk potential of 1.12%. On the other hand Halozyme Therapeutics has an analysts' consensus of $66.11 which suggests that it could grow by 6.2%. Given that Halozyme Therapeutics has higher upside potential than Exelixis, analysts believe Halozyme Therapeutics is more attractive than Exelixis.

Exelixis has a beta of 0.571, which suggesting that the stock is 42.856% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.323, suggesting its more volatile than the S&P 500 by 32.293%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are larger than Halozyme Therapeutics quarterly revenues of $298M. Exelixis's net income of $139.9M is higher than Halozyme Therapeutics's net income of $137M. Notably, Exelixis's price-to-earnings ratio is 20.71x while Halozyme Therapeutics's PE ratio is 18.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.00x versus 7.93x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Incyte has a net margin of 24.68% compared to Exelixis's net margin of 17.07%. Exelixis's return on equity of 23.63% beat Incyte's return on equity of 0.81%.

Exelixis has a consensus price target of $37.06, signalling upside risk potential of 1.12%. On the other hand Incyte has an analysts' consensus of $78.26 which suggests that it could grow by 15.32%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

Exelixis has a beta of 0.571, which suggesting that the stock is 42.856% less volatile than S&P 500. In comparison Incyte has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.262%.

Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.

Exelixis quarterly revenues are $566.8M, which are smaller than Incyte quarterly revenues of $1.2B. Exelixis's net income of $139.9M is lower than Incyte's net income of $201.2M. Notably, Exelixis's price-to-earnings ratio is 20.71x while Incyte's PE ratio is 251.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.00x versus 3.39x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.